Can CSF biomarkers or pre‐treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease?
The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.
Abstract
Objective: The main objective of this study was to investigate possible predictors of response to cholinesterase inhibitor (ChEI) treatment, including pre‐treatment progression rates and levels of the cerebrospinal fluid (CSF) biomarkers. A secondary objective was to evaluate whether treatment with ChEI changed progression. Methods: Out‐patient individuals (n = 191) with the clinical diagnosis of Alzheimer's disease received ChEI treatment and were part of the Swedish Alzheimer Treatment Study (SATS), a prospective, longitudinal, non‐randomised study in a routine clinical setting. Patients were assessed with MMSE, ADAS‐cog and a global rating (CIBIC) at baseline, 2 months and every 6 months for a total period of 3 years. The following potential predictors of treatment response were investigated: age, gender, APOE ε 4 carrier, education, duration of disease, cognitive level, pre‐treatment progression rate (in MMSE) and the levels of the CSF biomarkers A β 42, T‐tau and P‐tau. Results: Fast pre‐treatment progression rate was a predictor of treatment response even after adjusting for baseline severity, another positive predictor of response. Patients in the fastest quartile of pre‐treatment progression rates were significantly more prone to be responders at 2 months (adjusted OR 6.6, p = 0.001) and 6 months (adjusted OR 10.4, p < 0.001) than those in the slowest progressing quartile. Moreover, the linearity of progression was significantly changed by ChEI treatment at 6 months compared to the pre‐treatment period. Conclusion: The rate of pre‐treatment progression was the most consistent positive predictor of ChEI treatment response in the routine clinical setting. The progression rate was significantly changed by ChEI treatment. Copyright © 2009 John Wiley & Sons, Ltd.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Neuropathological stageing of Alzheimer-related changes.
Braak, H., & Braak, E. (1991) · Acta Neuropathologica · doi:10.1007/bf00308809 · Cited by 16,123
The cholinergic hypothesis of Alzheimer’s disease: A review of progress
Francis, P. T., Palmer, A. M., Snape, M., & Wilcock, G. K. (1999) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.66.2.137 · Cited by 2,198
Cholinesterase inhibitors for Alzheimer's disease
Birks, J. S. (2006) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd005593 · Cited by 1,906
Hansson, O., Zetterberg, H., Buchhave, P., Londos, E., Blennow, K., & Minthon, L. (2006) · The Lancet Neurology · doi:10.1016/s1474-4422(06)70355-6 · Cited by 1,700 · cited 2×
“CSF biomarkers are powerful state markers for AD even in the MCI phase of the disease (Hansson et al., 2006) and the individual levels have been shown to be stable over a 6 month period of ChEI treatment (Blennow et al.”
BackgroundSelf-citationEvaluation of CSF-tau and CSF-Aβ42 as diagnostic markers for Alzheimer disease in clinical practice
Andreasen, N., Minthon, L., Davidsson, P., Vanmechelen, E., Vanderstichele, H., Winblad, B., & Blennow, K. (2001) · Archives of Neurology · doi:10.1001/archneur.58.3.373 · Cited by 573
Self-citationHan, L., Cole, M., Bellavance, F., McCusker, J., & Primeau, F. (2000) · International Psychogeriatrics · doi:10.1017/s1041610200006359 · Cited by 202 · cited 1×
“This is very close to expected MMSE changes in untreated AD patients where annual declines between 2–4 points a year have been described (Salmon et al., 1990; Han et al., 2000).”
BackgroundAccelerated decline in apolipoprotein E-ϵ4 homozygotes with Alzheimer's disease
Craft, S., Teri, L., Edland, S. D., Kukull, W. A., Schellenberg, G., McCormick, W. C., Bowen, J. D., & Larson, E. B. (1998) · Neurology · doi:10.1212/wnl.51.1.149 · Cited by 152
Wallin, Å. K., Andreasen, N., Eriksson, S., Båtsman, S., Näsman, B., Ekdahl, A., Kilander, L., Grut, M., Rydén, M., Wallin, A., et al. (2007) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000098052 · Cited by 84 · cited 2×
“This deficiency is currently a target of therapy since cholinesterase inhibitor (ChEI) treatment enhances the cholinergic transmission in AD and shows beneficial effects on cognition in both placebo controlled and open studies (Birks, 2006; Wallin et al., 2007).”
BackgroundWallin, Å. K., Gustafson, L., Sjögren, M., Wattmo, C., & Minthon, L. (2004) · Dementia and Geriatric Cognitive Disorders · doi:10.1159/000079201 · Cited by 45
Self-citation
Cited by
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
Blennow, K., Hampel, H., Weiner, M., & Zetterberg, H. (2010) · Nature Reviews Neurology · doi:10.1038/nrneurol.2010.4 · Cited by 1,863
Self-citationClinical utility of cerebrospinal fluid biomarkers in the diagnosis of early Alzheimer's disease
Blennow, K., Dubois, B., Fagan, A. M., Lewczuk, P., de Leon, M. J., & Hampel, H. (2015) · Alzheimer's & Dementia · doi:10.1016/j.jalz.2014.02.004 · Cited by 455
Self-citationFluid Biomarkers in Alzheimer Disease
Blennow, K., Zetterberg, H., & Fagan, A. M. (2012) · Cold Spring Harbor Perspectives in Medicine · doi:10.1101/cshperspect.a006221 · Cited by 208
“Cite this article as Cold Spring Harb Perspect Med doi: 10.1101/cshperspect.a006221 w w w .p er sp ec ti ve si n m ed ic in e. o rg AD cases (Samgard et al. 2009; Wallin et al. 2009).”
BackgroundInfluentialSelf-citationReimagining cholinergic therapy for Alzheimer’s disease
Giacobini, E., Cuello, A. C., & Fisher, A. (2022) · Brain · doi:10.1093/brain/awac096 · Cited by 187
Wattmo, C., Blennow, K., & Hansson, O. (2020) · BMC Neurology · doi:10.1186/s12883-019-1591-0 · Cited by 93
Self-citation
Metadata
- Authors
- Wallin, Å. K., Hansson, O., Blennow, K., Londos, E., & Minthon, L.
- Venue
- International Journal of Geriatric Psychiatry
- Publisher
- Wiley
- Published
- 2009-01-02
- Volume
- 24
- Issue
- 6
- Pages
- 638-647
- ISSN
- 0885-6230 (ISSN-L)
- 1099-1166
- OpenAlex
- W1967582720
- Cited by
- 37
- References
- 9
- FWCI
- 2.77
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Can CSF biomarkers or pre‐treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? https://app.cochat.ai/papers/10.1002/gps.2195
- The paper
- Wallin, Å. K., Hansson, O., Blennow, K., Londos, E., & Minthon, L. (2009). Can CSF biomarkers or pre‐treatment progression rate predict response to cholinesterase inhibitor treatment in Alzheimer's disease? International Journal of Geriatric Psychiatry. https://doi.org/10.1002/gps.2195
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.